Rifabutin Is Active against Mycobacterium abscessus in Mice

There is no reliable cure for Mycobacterium abscessus lung disease. Rifampin is not used clinically due to poor in vitro potency. In contrast, we have shown that rifabutin, another approved rifamycin used to treat tuberculosis, is potent in vitro against M. abscessus. Here, we report that rifabutin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dick, Thomas, Shin, Sung Jae, Koh, Won-Jung, Dartois, Véronique, Gengenbacher, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985736/
https://www.ncbi.nlm.nih.gov/pubmed/31767722
http://dx.doi.org/10.1128/AAC.01943-19
_version_ 1783491862172008448
author Dick, Thomas
Shin, Sung Jae
Koh, Won-Jung
Dartois, Véronique
Gengenbacher, Martin
author_facet Dick, Thomas
Shin, Sung Jae
Koh, Won-Jung
Dartois, Véronique
Gengenbacher, Martin
author_sort Dick, Thomas
collection PubMed
description There is no reliable cure for Mycobacterium abscessus lung disease. Rifampin is not used clinically due to poor in vitro potency. In contrast, we have shown that rifabutin, another approved rifamycin used to treat tuberculosis, is potent in vitro against M. abscessus. Here, we report that rifabutin is as active as clarithromycin against M. abscessus K21 in NOD.CB17-Prkdc(scid)/NCrCrl mice. This suggests that rifabutin should be considered a repurposing candidate for patients with M. abscessus disease.
format Online
Article
Text
id pubmed-6985736
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-69857362020-02-11 Rifabutin Is Active against Mycobacterium abscessus in Mice Dick, Thomas Shin, Sung Jae Koh, Won-Jung Dartois, Véronique Gengenbacher, Martin Antimicrob Agents Chemother Experimental Therapeutics There is no reliable cure for Mycobacterium abscessus lung disease. Rifampin is not used clinically due to poor in vitro potency. In contrast, we have shown that rifabutin, another approved rifamycin used to treat tuberculosis, is potent in vitro against M. abscessus. Here, we report that rifabutin is as active as clarithromycin against M. abscessus K21 in NOD.CB17-Prkdc(scid)/NCrCrl mice. This suggests that rifabutin should be considered a repurposing candidate for patients with M. abscessus disease. American Society for Microbiology 2020-01-27 /pmc/articles/PMC6985736/ /pubmed/31767722 http://dx.doi.org/10.1128/AAC.01943-19 Text en Copyright © 2020 Dick et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Experimental Therapeutics
Dick, Thomas
Shin, Sung Jae
Koh, Won-Jung
Dartois, Véronique
Gengenbacher, Martin
Rifabutin Is Active against Mycobacterium abscessus in Mice
title Rifabutin Is Active against Mycobacterium abscessus in Mice
title_full Rifabutin Is Active against Mycobacterium abscessus in Mice
title_fullStr Rifabutin Is Active against Mycobacterium abscessus in Mice
title_full_unstemmed Rifabutin Is Active against Mycobacterium abscessus in Mice
title_short Rifabutin Is Active against Mycobacterium abscessus in Mice
title_sort rifabutin is active against mycobacterium abscessus in mice
topic Experimental Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985736/
https://www.ncbi.nlm.nih.gov/pubmed/31767722
http://dx.doi.org/10.1128/AAC.01943-19
work_keys_str_mv AT dickthomas rifabutinisactiveagainstmycobacteriumabscessusinmice
AT shinsungjae rifabutinisactiveagainstmycobacteriumabscessusinmice
AT kohwonjung rifabutinisactiveagainstmycobacteriumabscessusinmice
AT dartoisveronique rifabutinisactiveagainstmycobacteriumabscessusinmice
AT gengenbachermartin rifabutinisactiveagainstmycobacteriumabscessusinmice

Ejemplares similares